Actively Recruiting
SiREX-Stent for the Treatment of SymptOmatic Lateral VEnous Sinus Stenosis
Led by Acandis GmbH · Updated on 2025-09-04
78
Participants Needed
1
Research Sites
174 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of the study is to assess the efficacy, safety and the clinical benefit of the SiREX stent for the treatment of disabling pulsatile tinnitus due to stenosis of lateral sinus. The study will enrol patients suffering from pulsatile tinnitus related to a lateral sinus stenosis lasting more than three months, and who want to be treated with lateral sinus stenting
CONDITIONS
Official Title
SiREX-Stent for the Treatment of SymptOmatic Lateral VEnous Sinus Stenosis
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patient is 18 years old or older
- Disabling pulsatile tinnitus lasting more than three months
- Pulsatile tinnitus is interrupted by compression of the same side jugular vein
- Lateral sinus stenosis visible on venous MRA or venous angio CT
- Other causes of pulsatile tinnitus excluded on MRI and temporal bone CT except lateral sinus dehiscence related to stenosis
- Stenosis located on a dominant or codominant lateral sinus
- Pressure gradient of at least 3 mm Hg under general anesthesia if no sinus dehiscence, or at least 2 mm Hg if sinus dehiscence present
- Patient requests treatment of their pulsatile tinnitus
- Patient agrees to receive the SiREX Stent instead of a carotid stent
- Written informed consent provided
You will not qualify if you...
- Pulsatile tinnitus that is non-pulsatile or unrelated to lateral sinus stenosis
- Stenosis with pressure gradient less than 2 mm Hg without associated lateral sinus dehiscence
- Contraindications for treatment per Instructions for Use, including:
- Venous vessel size outside stent range
- Anatomic morphology unsuitable for endovascular treatment due to severe vessel tortuosity or stenosis
- No pre-treatment with antiplatelet agents before procedure
- Contraindication to antiplatelet and/or anticoagulant therapy
- Acute subarachnoid hemorrhage
- Active bacterial infection
- Hypersensitivity to nickel-titanium
- Pregnant or breastfeeding women
- Participation in another clinical study
- Life-threatening event in the last 6 months
- Life expectancy under 12 months
- Severe comorbidities likely to prevent follow-up visits (e.g., cancer, substance abuse, dementia)
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Hôpital Lariboisière
Paris, France, 75010
Actively Recruiting
Research Team
A
Anna Gold
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here